Universal Time: 14:54  |  Local Time: 14:54 (0h GMT)
Select your timezone:
Reset

Sun Sep 13

00:00 Symposium: Lessons Learned about COVID-19
105.4 Immunogenetics (HLA and ABO)
Lori Jeanne West, Canada
105.6 Global Impact of COVID-19 on Transplantation
Alexandre Loupy, France
105.1 Virology, Epidemiology and Clinical Course
Olivia S. Kates, United States
105.2 Organ Specific Involvement of COVID-19
Aneesha Anand Shetty, United States
105.3 Diagnostics:  PCR, Antigen Detection and Serology 
Robin Patel, United States
105.5 Therapeutics & Vaccines
Michael G. Ison, United States
00:00 Symposium: Transplanting in the Era of COVID-19
110.2 When a Recipient with COVID-19 Can Proceed to Transplant
Paolo Antonio Grossi, Italy
110.1 Donor Screening and the Risk of Virus Transmission
Thomas D. Mone, United States
110.4 Transplantation in the Hot Zone
Jean C. Emond, United States
110.3 Lung Transplantation for COVID-19
Jingyu Chen, People's Republic of China
110.5 Transplantation and Ethical Issues in the COVID Era: Doing the right thing depends on location, resources and disease burden
Peter G. Stock, United States
23:30 - 00:15 Oral Abstracts Session: Innate and Adaptive Immunity
211.1 Gasdermin-D mutation is protective against renal ischemia reperfusion injury
Jennifer Li, Australia
211.5 (P-2.74 in Journal) Oral administration of nano-sized silicon particles attenuates oxidative stress and ischemia-reperfusion injury in a rat model: A novel hydrogen administration method
Masataka Kawamura, Japan
211.3 Modulation of the IL-33/ST2 axis for regulatory T cell therapy in transplantation
Kento Kawai, United Kingdom
211.4 Development of fully differentiated pancreatic organoids from hiPSCs for type 1 diabetes cell therapy
Giuseppe Pettinato, United States

Mon Sep 14

00:15 - 02:00 State-of-the-Art Session: Tissue-Resident Lymphocytes
220.1 Formation and plasticity of tissue resident memory populations in human allografts revealed by single cell analysis and serial TCR sequencing
Megan Sykes, United States
220.2 Antigen presentation by tissue resident APC
Adrian E. Morelli, United States
220.3 Reshaping T cell memory with lymphoablation
Anna Valujskikh, United States
00:15 - 02:00 State-of-the-Art Session: Expanding the Donor Pool, Pushing the Limits
222.2 Use of DCD organs in heart and lung transplant
Gregory I Snell, Australia
222.1 Use of HCV positive organs into HCV negative recipients
David Goldberg, United States
222.3 Transplant outcomes from older donors > Age 60
Colleen L. Jay, United States
07:30 - 08:15 Oral Abstracts Session: Immune Regulation and Outcomes
251.2 Discovery of pMHC epitopes for directly alloreactive T cells
Eric Taeyoung ES Son, Australia
251.3 The Prediction of Kidney Allograft Acute Rejection Based on Recipient Peripheral Blood Whole Transcriptome Profiling and Three mRNA Molecular Signatures
Liao Minxue, People's Republic of China
251.4 Myeloid derived suppressor cells (MDSC) in kidney recipients: Identification of CD25+eMDSC, and augmentation of monocytic-MDSC early after transplantation in patients later developing cancer
Alberto Utrero-Rico, Spain
251.1 Elucidating the role of hypoxia in regulatory T cell function
Marie Sion, United Kingdom
08:15 - 10:00 State-of-the-Art Session: Managing Immunosuppression When Things Go Wrong
261.1 Managing IS in recipients with a failing graft
Sangho Lee, Korea
261.3 Managing IS in recipients treated for malignancies
Daniel Seron, Spain
261.2 Managing IS in recipients with complex infections
Peter Chin-Hong, United States
08:15 - 10:00 State-of-the-Art Session: Banff 2019 Update for Allograft Rejection
262.1 Liver (morphology)
Andrew Clouston, Australia
262.4 Kidney (molecular)
Carmen Lefaucheur, France
262.3 Kidney (morphology)
Hyeon Joo Jeong, Korea
262.2 Liver (molecular phenotyping)
Alberto Sanchez-Fueyo, United Kingdom
13:00 - 14:30 Workshop Session: Specific Challenges in Pediatric Transplantation
277.1 Research in paediatric transplantation
Stephen Alexander, Australia
Dr. Alexander Q&A discussion (4 minutes)
- -,
277.2 Transition
Lars Pape, Germany
277.3 Adherence
Bethany J. Foster, Canada
277.4 Steroids and growth
Ryszard Grenda, Poland
14:30 - 15:15 Oral Abstracts Session: Biomarkers and Omics
281.3 Single cell transcriptomic analysis for a better understanding of human CD8+ regulatory T cells
Céline Serazin, France
281.1 Transplantation of older organs transfers senescence
Jasper Iske, Germany
281.5 (P-2.125 in Journal) TCR repertoire sequencing of total T cells and circulating follicular helper T cells in kidney transplant recipients
Patricia Almendro Vázquez, Spain
281.2 Diagnosis of kidney transplant rejection by tracking donor-reactive T-cell clones in the post-transplant biopsy, blood and urine samples
Joseph R. Leventhal, United States
14:30 - 15:15 Oral Abstracts Session: Established IS
282.1 Country-dependent outcome differences after kidney transplantation in France vs. Germany – An additional analysis of the Athena study
Barbara Suwelack, Germany
282.3 Correlation of trough level compliance and protection of renal function after liver transplantation – A post-hoc analysis from the Hephaistos study
Björn Nashan, Germany
282.2 The risk of post-KT outcomes by induction choice differ between older and younger KT recipients
JiYoon Ahn, United States
282.4 Panel reactive antibody and the association of early steroid withdrawal with kidney transplant outcomes
Sunjae Bae, United States
23:30 - 00:15 Oral Abstracts Session: Experimental and Preclinical Immunosuppression
312.2 Targeting inflammatory monocytes by immune-modifying nanoparticles prevents acute kidney allograft rejection
Christina Lai, Australia
312.4 ABO self-tolerance in a mouse model: Evidence of tolerance at B cell but not T cell level
Ibrahim Adam, Canada
312.1 Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage CSF (GM-CSF) administration enriches for highly suppressive CD4+CD45RA-Foxp3hi cells in leukapheresis products of rhesus monkeys
Kazuki Sasaki, United States
312.3 Carfilzomib and lulizumab-based desensitization prolongs allograft survival in sensitized non-human primates kidney transplantation model
Jean Kwun, United States

Tue Sep 15

07:30 - 08:15 Oral Abstracts Session: Deceased Organ Donation
352.1 Predicting time to death after withdrawal in controlled donation after circulatory death (DCD) donors : A comparison of 100 DCD lung transplant (LTx) donors versus 59 potential DCD donors that did not progress
Bronwyn Levvey, Australia
352.3 Settling the difference: Analysis of kidney graft function discordance at transplant from deceased donor paired kidneys
Essa Abuhelaiqa, Qatar
352.2 Impact of explant biopsy assessments and kidney allocation on outcomes of expanded criteria donor kidney transplants versus standard criteria donor kidney transplants in an Asian transplant program
Yun Ting Yap, Singapore
352.4 Development of Thai Kidney Donor Profile Index (KDPI) and Estimated Post Transplant Survival (EPTS) score for predicting outcome after deceased donor kidney transplantation: Report from Thai Transplant Registry in conjunction with Thai Red Cross
Nuttasith Larpparisuth, Thailand
07:30 - 08:15 Oral Abstracts Session: Infectious Diseases
353.5 (P-9.02 in Journal) Impact of non-active hepatitis B on patient survival after renal transplantation
Marcel RG Naik, Germany
353.2 A recent diagnosis of tuberculosis is a risk factor for post-transplant morbidity & mortality after liver transplantation: A propensity score match-based analysis
Pradez Sapkota, India
353.3 Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab
Hyunwook Kwon, Korea
353.4 Gram negative blood stream infection in renal transplant recipients: Risk factors and outcome from a transplant center in Pakistan
Sunil Kumar Dodani, Pakistan
08:15 - 10:00 State-of-the-Art Session: The Future is Now… Immune Regulation in Transplantation
360.1 The Regulation of Immune Tolerance by FOXP3 - basic
Ling Lu, People's Republic of China
360.2 Intragraft immune regulation protects transplants under sub-therapeutic immunosuppression
Paloma Riquelme, Germany
James Alexander Hutchinson, Germany
360.3 Clinical experience of Treg therapy
Fadi Issa, United Kingdom
08:15 - 10:00 State-of-the-Art Session: The Future of Anesthesia and ICU in Organ Donation
362.1 Neurosurgery, critical care and anesthesia: integrated support for organ donation in China
Xiaoli Fan, People's Republic of China
362.3 How manage organ donation in ICUs during COVID 19 times
Marco Sacchi, Italy
362.2 How can artificial intelligence, robotics and blockchain improve donor maintenance and treatment?
Jordi Colomer, Spain
14:30 - 15:15 Oral Abstracts Session: Immune Regulation and Tolerance I
381.4 Single cell immune profiling of human intestinal allografts reveals heterogeneity and alloreactivity of recipient resident memory T cells in association with graft outcomes
Jianing Fu, United States
381.1 Treg use the PD-1-PD-L1 axis for lymphatic transendothelial migration
Wenji Piao, United States
381.2 Donor liver plasmacytoid dendritic cells promote effector T cell exhaustion and augment Treg responses in mouse spontaneous liver transplant tolerance
Ryosuke Nakano, United States
381.3 Lymph node stromal laminin alpha 5 regulates adaptive immunity
Lushen Li, United States
15:15 - 17:00 State-of-the-Art Session: Novel Insights in Allorecognition
391.3 Non-HLA allorecognition and graft loss
Roman Reindl-Schwaighofer, Austria
391.2 T-cell allorecognition
Gavin Pettigrew, United Kingdom
391.1 Innate allorecognition
Fadi G. Lakkis, United States
15:15 - 17:00 State-of-the-Art Session: How Sex Impacts Post-Transplant Course
392.2 Sex differences in infection risks and vaccine responses
Deepali Kumar, Canada
392.1 Sex differences in cancer risk post-transplant
Anna Buxeda, Spain
392.3 Sex and the heart: Major cardiovascular events in transplantation
Darshana Dadhania, United States
15:15 - 17:00 State-of-the-Art Session: VCA: Cutting Edge Advances and Applications
393.1 Calcineurin-free immunosuppression in VCA – Outcomes and opportunities
Linda C. Cendales, United States
393.2 Regenerative surgery – The new realm
Giuseppe Orlando, United States
393.3 Cell targeted nanoimaging for graft surveillance – Advances in solid organ and VCA applications
Jelena M. Janjic PhD, United States
393.4 Biomarker surrogates for immune monitoring of VCA
Helen Stark, United Kingdom
23:30 - 00:15 Oral Abstracts Session: Living Organ Donation
411.3 When length becomes less: Minimum renal artery length required in left laparoscopic live donor nephrectomy
Anant Kumar, India
411.1 Impact of extended living donor criteria on donor safety in living donor liver transplantation
Joo Dong Kim, Korea
411.2 Evolution of right laparoscopic nephrectomy: Report of a tertiary care center in Mexico
LORENA NORIEGA-SALAS, Mexico
411.4 Determination of type 2 diabetes mellitus risk in potential living kidney donors: A single center protocol and experience
Golnaz G Friedman, United States
23:30 - 00:15 Oral Abstracts Session: Cell and Novel Therapies
412.1 Human mesenchymal-stem-cells derived exosomes play important roles in enhancing CB-treg suvival and functional stability
Juan Zhang, People's Republic of China
412.3 Targeting CD4+ T cell metabolism provides an effective and age-specific immunosuppression
Yeqi Nian, People's Republic of China
412.2 Phase 2 study design evaluating efficacy, safety, pharmacokinetics and pharmacodynamics of the anti-CD40 monoclonal antibody CFZ533 (iscalimab) in de novo liver transplant recipients: The CONTRAIL I study
Björn Nashan, Germany
412.4 Long-term follow-up of a phase 2 clinical trial to induce tolerance in living donor renal transplant recipients
Joseph R. Leventhal, United States

Wed Sep 16

00:15 - 02:00 State-of-the-Art Session: Preventable Infections - An Ounce of Prevention...
420.2 Screening and decolonization of MDROs pre-transplant: Is there a role?
Stephanie Pouch, United States
420.1 Respiratory viruses - Impact on our recipients
Michael G. Ison, United States
420.3 Keeping the fungi out of the transplant ward
Monica Slavin, Australia
00:15 - 02:00 Workshop Session: Upcoming Issues in the Diagnosis of Transplant Rejection
423.3 Dilemmas in renal allograft biopsy diagnosis
Brian J Nankivell, Australia
423.2 Gene expression in transplant tissue and body fluid
Michael Mengel, Canada
423.1 Digital pathology and machine learning in renal transplant pathology
Alton "Brad" Farris, United States
06:00 - 07:30 Workshop Session: Unique Aspects of Organ Donation and Assessment in Pediatric Transplantation
442.1 Risks for the living donor
Michael Kaabak, Russian Federation
442.2 Culture and religious perspectives
Jun Oh, Germany
442.4 ABO- and HLA- Incompatible transplantation
Seiichiro Shishido, Japan
442.3 Challenges of small paediatric donors
Nam-Joon Yi, Korea
07:30 - 08:15 Oral Abstracts Session: Immune Regulation and Tolerance II
451.3 PD-L1 / PD-1 interactions are critical for tolerance induction in primed skin graft recipients following liver-directed MHC class I gene transfer
Mario L Leong, Australia
451.2 Identification and isolation of human HLADR+ CD27+ Treg as xeno-antigen Treg subset for xenotransplantation
Xiaoqian Ma, People's Republic of China
451.1 Transient antibody targeting of CD45RC to prevent the development of acute graft versus host diseases
Carole Guillonneau, France
451.4 CTLA-4-Ig prolongs graft survival specifically in young but not in old recipients
Jasper Iske, Germany
07:30 - 08:15 Oral Abstracts Session: Organ Preservation and Reperfusion Injury / Repair
452.1 Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, improves donor heart recovery after prolonged cold storage in an isolated working rat heart model
Jeanette E. Villanueva, Australia
452.2 A single-centre, five-year experience with DCD heart transplantation
Sarah E Scheuer, Australia
452.3 (P-4.59 in Journal) NAPLES study (Normothermic machine perfusion of the liver to enable the sickest first): Preliminary results
Hanns Lembach, United Kingdom
452.4 Enhanced functional recovery of hearts donated after circulatory death (DCD) with ante-mortem heparin.
Ling Gao, Australia
07:30 - 08:15 Oral Abstracts Session: Education and Vascularized Composite Allograft
453.4 Organ donation innovative strategies for Southeast Asia: ODISSeA
María Paula Gómez, Spain
453.5 (P-5.02 in Journal) EUDONORGAN – Innovative European project training and social awareness for increasing organ donation
Marti Manyalich Vidal, Spain
453.2 Adipose derived mesenchymal stem cell delivered endothelial protection during graft vasculopathy during vascularized composite tissue allotransplantation
Pranitha Kamat, Switzerland
453.3 Desensitization using costimulatory blockade and bortezomib in reconstructive transplantation
Byoung Chol Oh, United States
13:00 - 14:30 Workshop Session: Determination of Death in Organ Donation
476.1 MAID in Canada
Matthew J Weiss, Canada
476.2 Global project on death determination
Gene Sung, United States
13:00 - 14:30 Workshop Session: CMV - What's New
477.3 New risks for CMV in solid organ and stem cell transplant recipients
José Maria Aguado, Spain
477.1 New drugs against an old foe
Francisco M Marty, United States
477.2 Immune monitoring
Camille Nelson Kotton, United States
14:30 - 15:15 Oral Abstracts Session: Donation Issues
481.4 Evaluation of the mechanism of action of hepatic hypothermic oxygenated machine perfusion (HOPE) using microdialysis in a clinical setting
Damiano Patrono, Italy
481.1 Consent to organ offers from public health service “increased risk” donors decreases time to transplant and waitlist mortality
Yvonne Kelly, United States
481.2 Executive order on advancing american kidney health: A Markov analysis of long-term costs
Rashikh A Choudhury, United States
481.3 Outcomes of non-liver solid organ transplantation using hepatitis C positive donors to hepatitis C negative recipients: A multicenter experience
Kristen L Ryland, United States
15:15 - 17:00 State-of-the-Art Session: Sex as an Immunological Variable
490.3 The role of the X chromosome in organ transplantation
Anette Melk, Germany
490.1 Improved renal ischemia tolerance in females influences kidney transplantation outcomes
Matthew Levine, United States
490.2 Sex as a biological variable
Stefan G. Tullius, United States
15:15 - 17:00 State-of-the-Art Session: Paediatric Transplantation Around the World
491.1 Paediatric kidney transplantation around the world
Mignon McCulloch, South Africa
491.2 Cost Effective Immunosuppressive Medications Around the World
Katherine Twombley, United States
491.3 Variety of vaccine preventive paediatric infectious diseases around the world
Lara Danziger-Isakov, United States

E-Posters

Poster Session: Anesthesia Management and Critical Care
P-1.02 Intraoperative low-dose dexmedetomidine attenuates hepatic ischemia-reperfusion injury in pediatric living donor liver transplantation
Liang Zhang, People's Republic of China
P-1.05 Nutritional management to avoid metabolic decompensation at major surgeries in a patient with propionic acidemia related cardiomyopathy: A case report
Hiromi Takenaka, Japan
P-1.03 Clinical outcomes of influenza infection among solid organ transplant recipients in ICU
Pinar Zeyneloglu, Turkey
P-1.04 Solid organ transplant recipients with pneumonia in intensive care unit: A single center study
Pinar Zeyneloglu, Turkey
Poster Session: Cellular and Regenerative Therapies
P-3.06 Generation of stable human induced regulatory T-cells requires optimal rapamycin concentration and TCR stimulation
Juewan Kim, Australia
P-3.11 Small-for-size syndrome is characterized with PD-L1 upregulation in macrophage and blocking PD-L1 accelerates liver regeneration
Ji-Hua Shi, People's Republic of China
P-3.14 Directed differentiation of iPS into imDCs under the action of SN can induce immunoreactivity in vitro
Cuixiang Xu, People's Republic of China
P-3.15 Sinomenine enhances imDC derived from IPS cell-directed differentiation to induce transplant immune hyporesponsiveness in mouse
Cuixiang Xu, People's Republic of China
P-3.03 Cell therapy using CD8+Tregs in human transplantation
Séverine Bézie, France
P-3.10 Bile duct reconstruction using scaffold-free tubular constructs created by a Bio-3D Printer for transplantation
Takashi Hamada, Japan
P-3.13 Visual rehabilitation after penetrating keratoplasty
Leyla Asena, Turkey
P-3.16 Limbal stem cell transplantation for restoration of the ocular surface health in bilateral limbal stem cell deficiency
Dilek Dursun Altinors, Turkey
P-3.01 Mass Cytometry Analysis of the Peripheral Regulatory T cell Compartment after Cellular Therapy in Renal Transplantation
Alaa Alzhrani, United Kingdom
P-3.08 Successful induction of hematopoietic chimerism by MCL-1 and Bcl-2 inhibition without radiation/chemo therapy in nonhuman primates
David Ma, United States
Poster Session: Donation and Procurement
P-4.03 Sharing of deceased donor livers in Australia and New Zealand
Michael Fink, Australia
P-4.04 Removing the BMI bias in kidney transplantation: Outcomes of kidney transplantation in patients with BMI >35
Aaron YS Hui, Australia
P-4.05 Clinician perspectives on factors associated with delayed wait-listing for deceased donor renal transplantation in Australia
Lachlan McMichael, Australia
P-4.10 Missed opportunities for organ donation from potential donors with primary brain tumours in Australia; cohort study 2010-2015
Imogen Thomson, Australia
P-4.12 Verification of suspected melanomas in deceased organ donor referrals: A population-based cohort study using data-linkage, 2010-2015
Brenda Marie Rosales, Australia
P-4.15 It’s not too late to donate...Controlled Donation after Circulatory Death (DCD) of lungs up to 24 hours after Withdrawal of Cardio Respiratory Support (WCRS)
Katherine Labib, Australia
P-4.16 Perceived vs. verified risk of cancer transmission from deceased organ donors: a 2010-2015 cohort study using data linkage in New South Wales, Australia
James A. Hedley, Australia
P-4.51 Kidney Paired Donation In Brazil
Gustavo Fernandes Ferreira, Brazil
P-4.44 Health professional level barriers to living donor kidney transplantation: A mixed methods study
Renata Iskander, Canada
P-4.11 A prediction model of delay graft function from deceased donor risk factor: A multi-center study from China
Wujun Xue, People's Republic of China
P-4.23 Organ donation, a new subject developed in China towards professionalism
Wenshi Jiang, People's Republic of China
P-4.56 A systematic review of physicians’ and patients’ preferences regarding the allocation of deceased donor organs: To what extent are physicians acting as advocates for their patients?
Tim Bartling, Germany
P-4.57 Systematic review and focus group discussions of public preferences for the allocation of deceased donor organs as preliminary works: Building a discrete choice experiment evaluating principles of distributive justice
Carina Oedingen, Germany
P-4.35 Asymptomatic donor stones: Management algorithm
Anant Kumar, India
P-4.38 Comparative analysis of live donor kidney transplantation in double renal arteries with 30/70 lumen discrepancy using Pajama Bench reconstruction versus end to side reconstruction and separate implantation technique
Anant Kumar, India
P-4.24 Ten recommendations on approaching next of kin for consenting organ donation; Or How did we manage to increase consent rates by 64%?
Omid Ghobadi, Iran (Islamic Republic of)
P-4.30 National implementation of Persian possible donor detection program: An 8-month efficiency evaluation
Ali Etemadi, Iran (Islamic Republic of)
P-4.49 Minimum incision open donor nephrectomy versus laparoendoscopic single-site donor nephrectomy: A possible safe alternative
Kentaro Ide, Japan
P-4.32 The meaning of kidney transplantation from circulatory death donor in local hospital
Shin Do Suh, Korea
P-4.41 Predictors for renal outcome in living kidney donors: From data of Korean organ transplantation registry
Yunmi Kim, Korea
P-4.48 Living liver donor surgical complication : Single center experience
Eun-Kyoung Jwa, Korea
P-4.40 Comparative analysis of donor and allograft outcomes based on laterality of kidney donation: proof of equivalence of the safety and efficacy of laparoscopic left versus right donor nephrectomy
Dinno Francis A Mendiola, Philippines
P-4.46 Laparoscopic left lateral sectionectomy in living liver donors: From the first experience to routine usage
Konstantin O. Semash, Russian Federation
P-4.14 Benefits of kidney transplantation in Asians - A comparison of survival of kidney transplant recipients and wait-listed patients remaining on dialysis in Singapore
Terence Kee Yi Shern, Singapore
P-4.19 Experiences with expanded criteria donors: 10-year analysis of the Martin, Slovakia Transplant Center
Ivana Dedinska, Slovakia (Slovak Republic)
P-4.13 Impact of controlled donation after circulatory death (cDCD) on waiting list mortality for liver transplantation in the last 10 years: The Spanish experience
Felipe Alconchel, Spain
P-4.22 ISO quality certification for a hospital-based organ procurement unit: The United Arab Emirates (UAE) experience
María Paula Gómez, Spain
P-4.34 Implementation of a mobile ECMO team for normothermic regional perfusion as donor preservation method in Controlled Donation After Circulatory death (CDAC) in the community of Madrid
ALONSO MATEOS RODRIGUEZ, Spain
P-4.21 Deceased-donor transplantation activities in Turkey
Ebru Hatice Ayvazoglu Soy, Turkey
P-4.07 Histopatological grade of ischemia reperfusion injury on short- and long-term outcomes in liver transplantation using DCD (deceased after circulatory death donor) grafts
Annalisa Dolcet, United Kingdom
P-4.08 Deceased kidney donor pre-procurement cardiac arrest associated with better long-term graft survival
Shivani Bajpai, United States
P-4.18 Zero organ, one organ, and authorized-not recovered donors: Trends and opportunities in a growing organ procurement organization
Jeffrey P. Orlowski, United States
P-4.47 Robotic versus open mini incision living donor nephrectomy: Single center experience
Seung Duk Lee, United States
P-4.84 Implementation of a national organ matching and data system for Australian solid organ transplantation programs
Rhonda Holdsworth, Australia
P-4.100 Burnout and resilience among organ donation coordinators: A scoping review
Vanessa Silva e Silva, Canada
P-4.102 Bric study - Burnout and resiliency levels among organ donation coordinators: Research protocol
Vanessa Silva e Silva, Canada
P-4.61 Brain death-mediated inflammatory liver injury is mediated by hepatocytes apoptosis through TRAIL
Zhong-kun Huo, People's Republic of China
P-4.69 Double-lobectomy in rat model of steatotic liver transplantation
Fu Zhen, People's Republic of China
P-4.73 Value of CTGF in assessment of liver graft with non-alcoholic fatty liver disease after brain death
Dongjing Yang, People's Republic of China
P-4.96 Tetramethylpyrazine activated PPARγ in resuscitating the liver graft donated after cardiac death
Fu Zhen, People's Republic of China
P-4.111 Enabling legal provisions and their crucial role in promoting organ donation and transplantation – The Indian scenario
Vasanthi Ramesh M.S., FALS, India
P-4.70 Lessons learned from perfusate analysis during dual hypothermic oxygenated machine perfusion of liver grafts
Damiano Patrono, Italy
P-4.103 The role of cooperation programs including education of tissue and organ transplant coordinators and collaboration with Japan Organ Transplant Network on heart valve donation in west Japan
Norihide Fukushima, Japan
P-4.107 Deceased donor tissue recovery activity in Eastern Japan
Sayaka Nagashima, Japan
P-4.101 Causes of lowered family consent rate for organ donation
Eunsuk Yu, Korea
P-4.87 Brain death donation improvement areas: Procurement impact
Olga E Facio, Mexico
P-4.65 Does the cold storage really «cold»? Liver thermography and microdialysis findings
Alexander I Sushkov, Russian Federation
P-4.74 Observations on 24-hour ex situ normothermic liver perfusion
Amelia J Hessheimer, Spain
P-4.80 New technique for abdominal wall retrieval: Our initial outcomes with the new technique in non-vascularized fascia
Iago Justo Alonso, Spain
P-4.81 Quorum: IT tool for organ donation quality system management: Pilot program in the Kingdom of Saudi Arabia
Estephan Arredondo, Spain
P-4.82 Implementation results of the first hospital-based organ procurement unit in Kerala (India)
María Paula Gómez, Spain
P-4.92 Protocol based on hepatitis C virus nucleic acid testing to optimize renal transplant from seropositive donors to seronegative recipients. An European experience
antonio franco, Spain
P-4.98 International Registry In Organ Donation and Transplantation (IRODAT) – 2019 worldwide data
María Paula Gómez, Spain
P-4.99 Heart transplantation from controlled donors: First case report in Spain
ALONSO MATEOS RODRIGUEZ, Spain
P-4.83 Readiness of the retrieval team for deceased donor kidney transplantation in Thailand
Korntip Phonphok, Thailand
P-4.94 Evaluation of one year, five years and ten years life time of patients with kidney transplant: Single-center experience
Mehmet Fethullah Aydin, Turkey
P-4.110 Establishment of solid organ transplantation in the United Arab Emirates
Shiva Kumar, United Arab Emirates
P-4.112 Establishment of liver transplantation in the United Arab Emirates from deceased and living donors
Shiva Kumar, United Arab Emirates
P-4.62 Bridging the gap: normothermic perfusion of discarded livers significantly alleviates the donor shortage in the United States
Siavash Raigani, United States
P-4.66 Real-time viability assessment during normothermic machine perfusion with Raman spectroscopy
Reinier de Vries, United States
P-4.76 Using pulsatile perfusion to successfully transplant kidneys with 15 percent glomerulosclerosis
Marty T Sellers, United States
P-4.77 Deceased donor organ flush with equivalent volumes of HTK and UW at a single U.S. organ procurement organization
Richard S. Mangus, United States
P-4.79 Automated electronic referrals are changing donation
Wade Liu, United States
P-4.89 Salvaging discarded livers with normothermic machine perfusion: Is it worth the cost?
Reinier de Vries, United States
P-4.95 Liver transplantation of hepatitis C-viremic donors to hepatitis C naive recipients
Fidel Lopez-Verdugo, United States
P-4.97 Aggressive pursuit of liver only donors and their transplant outcomes: Should we continue?
Marty T Sellers, United States
P-4.109 Pancreas transplant in chronic kidney disease for type 1 diabetic patients
Rashikh A Choudhury, United States
P-4.85 Robotic versus laparoscopic living donor nephrectomy: A prospective study
Thanh-Tuan Nguyen, Viet Nam
Poster Session: Histocompatibility
P-7.07 Assessment of ABO-histocompatibility: Modernizing ABO antibody detection tools for use in transplantation
Anne Halpin, Canada
P-7.10 Can epitope matching outmatch traditional HLA matching?
Christian Unterrainer, Germany
P-7.04 Prospective de novo DSA monitoring in renal transplant patients
Efstratios Kasimatis, Greece
P-7.05 Angiotensin II Type 1 Receptor Antibodies: Risk for rejection and impaired graft function
Angeliki G. Vittoraki, Greece
P-7.14 Tregs monitoring before and after renal transplantation
Efstratios Kasimatis, Greece
P-7.06 Impact of delayed graft function on highly sensitized patients in deceased donor kidney transplantation
Seong Gyu Kim, Korea
P-7.11 Predictability of eplet mismatch to acute rejection in low level HLA antigen mismatched kidney transplantation: Validation analysis of Korean Organ Transplantation Registry (KOTRY) data
Jong Cheol Jeong, Korea
P-7.12 Evaluation of a novel ultra-high-resolution assay and analytic software for next generation sequencing based genotyping of 11 human leukocyte antigen loci
MIMI JANG, Korea
P-7.02 Medium to long term impact of pre transplant DSA on allograft outcomes in deceased donors transplants
Muhammad A Khurram, United Kingdom
P-7.08 Impact of induction regimen, human leukocyte antigen mismatches and steroid maintenance on recipient and graft survival with different glomerulonephridities
Samy M Riad, United States
Poster Session: Histopathology
P-8.03 Comprehensive assessment of deceased donor kidneys with clinical characteristics, pre-implant biopsy histopathology and hypothermic mechanical perfusion parameters is highly predictive of delayed graft function
Jin Zheng, People's Republic of China
P-8.04 The causes and clinical significance of cellular or fibrocellular crescents in renal allograft
Sung-Eun Choi, Korea
Poster Session: Sex and Gender in Transplantation
P-15.06 Living donor kidney transplantation: Overcoming sex disparity in Japan
Mikiko Yoshikawa, Japan
P-15.01 Pregnancy outcomes in 1164 female kidney transplant recipients
Lisa Coscia, United States
P-15.04 Is altruistic (non-directed) living kidney donation a realm of Caucasian females? Experience from a single center in the United States
Amit Sharma, United States
Poster Session: Transplant Complications
P-17.03 Spectrum and consistency of cancer outcomes in randomized trials in kidney transplant recipients: A systematic review
Eric Au, Australia
P-17.01 Risk of hematological malignancies in solid organ transplant recipients: a meta-analysis
Runchen Wang, People's Republic of China
P-17.08 The evaluation of safety and efficacy of PCSK9 inhibitor in patients with cardiac allograft vasculopathy and hypercholesterolemia
Kensuke Kuroda, Japan
P-17.07 NT-pro BNP, visceral fat area, cell membrane integrity and arterial stiffness in renal transplant recipients
Zbigniew Heleniak, Poland
P-17.06 Role of sex in post-transplant diabetes mellitus development: Are men and women equal?
Ivana Dedinska, Slovakia (Slovak Republic)
P-17.05 Thyroid cancer recurrence risk after transplantation: Single center experience
Neslihan Bascil Tutuncu, Turkey
Poster Session: Transplant Immunosuppression
P-18.02 Mycophenolate mofetil and the incidence of skin cancer in kidney transplant recipients
Sarah J. Yusuf, Nigeria
P-18.38 Feasibility of steroid-free tacrolimus-basiliximab immunosuppression in pediatric liver transplantation
Natalia Riva, Argentina
P-18.24 Effects of immunosuppression and adjuvant immune-targeted drugs in preventing HCC recurrence after liver transplantation
HAO XING, People's Republic of China
P-18.34 The feature of MDSCs in the long-term stable kidney transplant recipients after different immunosuppression therapy
Tian Puxun, People's Republic of China
P-18.05 Intensified vs. standard mycophenolate dosing during the first year after kidney transplantation
Mladen Knotek, Croatia
P-18.08 Once- versus twice-daily tacrolimus and graft survival
Christian Unterrainer, Germany
P-18.35 Athena vs Hephaistos - Are discontinuation rates in multicenter studies driven by facts or attitudes?
Björn Nashan, Germany
P-18.26 Mammalian target of rapamycin Inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late?
Kin Pan Au, Hong Kong
P-18.13 Efficacy and safety of everolimus with reduced calcineurin inhibitor regimen versus mycophenolic acid with standard calcineurin regimen in Asian de novo kidney transplant recipients: Two-year results from the subgroup analysis of TRANSFORM study
Yoshihiko Watarai, Japan
P-18.14 Two year outcomes of low-dose vs very low-dose extended-release tacrolimus / mycophenolate mofetil in de novo kidney transplantation: A multi-center randomized controlled trial
Shigeyoshi Yamanaga, Japan
P-18.40 Safety and efficacy of everolimus in maintenance kidney transplant patients: A 2-year post-marketing surveillance study in Japan
Yoko Watanabe, Japan
P-18.19 Low dose (4.5 mg/kg) of Thymoglobulin is effective to control T cells but not B cells and CD56dimCD57+, CD56dimNKG2A+ natural killer cells resulting in de novo donor-specific antibody formation and acute rejection in non-sensitized living donor kidney recipients with early steroid withdrawal
Sung Shin, Korea
P-18.22 Clinical study of standard- versus reduced-dose tacrolimus combined with generic mycophenolate mofetil in de novo kidney transplantation: A prospective randomized trial
Jun Bae Bang, Korea
P-18.28 Efficacy and safety of everolimus with reduced-exposure cyclosporine in de novo kidney transplant recipients: 24-month <em>post-hoc</em> analysis from the TRANSFORM study
Duck Jong Han, Korea
P-18.37 Efficacy and safety of everolimus in Korean kidney transplant recipients: Results from a prospective, open label, multicenter, single arm trial
Man Ki Ju, Korea
P-18.16 Kidney re-transplant: Single-center experience from MENA region
Osama Gheith, Kuwait
P-18.18 Single centre experience on ultra low dose Thymoglobulin as an induction agent in low immunological risk living kidney transplant recipients
Maisarah Jalalonmuhali, Malaysia
P-18.17 Unusual approach to assess induction therapy efficacy in kidney transplantation
Michael Kaabak, Russian Federation
P-18.36 Outcomes of everolimus after heart transplantation
Maria Simonenko, Russian Federation
P-18.20 Impact on short-term outcomes from a switch from a Cyclosporine-based to Tacrolimus-based immunosuppression protocol for kidney transplantation in an Asian transplant centre
Pei Wen Ong, Singapore
P-18.25 High intrapatient variability of tacrolimus exposure after liver transplantation as new marker of poor outcomes
CRISTINA DOPAZO, Spain
P-18.31 Analysis of Immunobiogram pharmacodynamic dose-response curves to immunosuppressants in kidney transplant recipients: Further results from Transbio Study
Julio Pascual, Spain
P-18.32 Milligram to milligram conversion of twice daily to once daily tacrolimus provides equivalent drug exposure in adult kidney transplant
Kanitha Tiankanon, Thailand
P-18.04 Management of peripheral facial palsy in kidney transplant patients: A case series
Malek Mojaat, Tunisia
P-18.03 The incidence of glucose impairment and new onset diabetes (NODAT) after renal transplant: A retrospective 12-month review at a single UK-centre.
John T Black, United Kingdom
P-18.09 Global, multicentre, non-interventional study to assess long-term outcomes in kidney transplant recipients converting from twice-daily, immediate-release tacrolimus to once-daily, prolonged-release tacrolimus: 4-year interim analysis of the CHORUS study
Swapneel Anaokar, United Kingdom
P-18.12 Long-term outcomes in kidney transplant recipients converting from twice-daily, immediate-release tacrolimus to once-daily, prolonged-release tacrolimus in Asian countries: 3-year interim analysis of the multicentre, non-interventional CHORUS study
Swapneel Anaokar, United Kingdom
P-18.15 Comparison of single-dose vs double dose Alemtuzumab in renal transplant recipients: A single centre experience
Avinash R Odugoudar, United Kingdom
P-18.06 Pediatric primary deceased-donor-kidney transplant-recipients outcomes by immunosuppression induction received in the United States
Samy M Riad, United States
P-18.07 Pediatric primary live-donor-kidney transplant-recipients outcomes by immunosuppression induction received in the United States
Samy M Riad, United States
Poster Session: Vascularized Composite Allotransplantation
P-20.01 Subcutaneous implantation of rapamycin impregnated scaffolds demonstrate the potential for localised islet graft immunosuppression
Francis Kette, Australia
P-20.03 Local delivery of FK506 to prevent VCA early acute rejection in a delayed mixed chimerism protocol
Marion P Goutard, United States

WebApp Sponsor

© 2020 TTS 2020